Slides From Hot Topics in NASH: Identifying and Managing High-Risk Patients

Expert faculty present key data on new NASH/NAFLD studies, diagnostic tools, and treatment options for your patients.
Kenneth Cusi, MD, FACP, FACE
Program Director
Brent A. Neuschwander-Tetri, MD
Format: Microsoft PowerPoint (.ppt)
File Size: 2.83 MB
Released: December 6, 2018

Acknowledgements

Provided by the American Gastroenterological Association

American Gastroenterological Association (AGA)
4930 Del Ray Avenue
Bethesda, MD 20814
Phone: (301) 654-2055
Fax: (301) 654-5920
Email: member@gastro.org

Produced in collaboration with
Endocrine Society Logo
Supported by educational grants from
Gilead Sciences, Inc.
Intercept Pharmaceuticals, Inc.

Related Content

Stephen A. Harrison, MD, COL (Ret.), FAASLD, explains how to interpret endpoints used in NASH studies so you can evaluate emerging treatments.

Stephen A. Harrison, MD, COL (Ret.), FAASLD Released: March 29, 2019

Kenneth Cusi, MD, FACP, FACE, explains how to interpret endpoints used in NASH studies so you can evaluate emerging treatments.

Kenneth Cusi, MD, FACP, FACE
Program Director
Released: March 29, 2019

Kenneth Cusi, MD, FACP, FACE, and Stephen A. Harrison, MD, COL (Ret.), FAASLD, explain how to interpret endpoints used in NASH studies so you can evaluate emerging treatments

Kenneth Cusi, MD, FACP, FACE
Program Director
Stephen A. Harrison, MD, COL (Ret.), FAASLD
Released: March 26, 2019

Raymond E. Soccio, MD, PhD, summarizes the roles of weight loss and diabetes drugs in NASH

Raymond E. Soccio, MD, PhD Released: March 7, 2019

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue